Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1988-3-8
|
| pubmed:abstractText |
In vitro differentiating agents causing little bone marrow aplasia have been proposed as a specific therapy of myelodysplastic syndromes with excess of blasts. A critical review of the published data is presented. The preliminary results of a cooperative protocol using very low dosage of cytosine arabinoside (3mg/m2/twice daily) with or without androgens are given.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0001-5792
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
78 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
109-15
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading |
pubmed-meshheading:3124432-Aged,
pubmed-meshheading:3124432-Cell Differentiation,
pubmed-meshheading:3124432-Cytarabine,
pubmed-meshheading:3124432-Drug Evaluation,
pubmed-meshheading:3124432-Drug Therapy, Combination,
pubmed-meshheading:3124432-Fluoxymesterone,
pubmed-meshheading:3124432-Humans,
pubmed-meshheading:3124432-Middle Aged,
pubmed-meshheading:3124432-Myelodysplastic Syndromes
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature.
|
| pubmed:affiliation |
Department of Nuclear Medicine, Institut National de la Santé, Hôpital Saint-Louis, Paris, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Review
|